Navigation Links
The World Leader in Molecular Breast Imaging to Premiere Largest Detector in the Industry
Date:6/2/2011

NEWPORT NEWS, Va., June 2, 2011 /PRNewswire/ -- Dilon Diagnostics will introduce the latest advancement in molecular breast imaging (MBI) this week at the Society of Nuclear Medicine (SNM) Meeting in San Antonio, Texas, with the premiere of its FDA-cleared Dilon 6800® Acella Gamma Camera system. To complement the already widely successful Dilon 6800® standard field-of-view imaging system, the new camera will feature a much larger MBI detector which will make Dilon the first company in the industry to offer customers a choice in detector sizes.

MBI, also referred to as Breast-Specific Gamma Imaging (BSGI), is a functional imaging technique increasingly being used in the diagnostic workup of patients with indeterminate mammograms, particularly for those with dense breasts. With more than 250,000 patients imaged worldwide and an expanding number of molecular imaging products, Dilon is leading the forefront in molecular imaging and supporting clinical data for early cancer diagnostics.  Dilon believes its continued success can, in part, be attributed to its focus on the individual needs of each healthcare facility and personalized healthcare by providing customers with ongoing advancements such as larger field-of-view detectors and products like GammaLoc® (the only FDA-cleared biopsy guidance platform for MBI).  

According to Robert G. Moussa, Chairman and CEO at Dilon Diagnostics, "With the increasing need to better serve a diversifying population of women, we feel it is crucial to provide additional solutions to help facilities reduce tiling, examination times and ultimately, continue to optimize their workflow."

"With the launch of the Acella," said Moussa, "I am proud to say that we are now the only molecular breast imaging company in the industry who has the unique capability of being able to offer customers a choice of imaging solutions."  

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view digital gamma camera, optimized for breast imaging (MBI/BSGI).  MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide the high photon sensitivity needed to perform low dose MBI/BSGI studies. Dilon's GammaLoc® System is the only localization device on the market to enable gamma-guided breast biopsy. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; Lahey Clinic, Boston; George Washington University, Washington D.C. For more information on Dilon Diagnostics please visit www.dilon.com.


'/>"/>
SOURCE Dilon Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... Splashtop Inc., the worldwide leader in high performance ... the leading provider of secure mobile remote access solution for Japan enterprises. ... remote access solution. Splashtop for CACHATTO will be available as an integrated ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... When ... he knew it was something that contractors should have at their disposal on ... gets,” says Butch, CertainTeed’s Director of Contractor Programs. , As a result, ...
(Date:5/31/2016)... Severna Park, Maryland (PRWEB) , ... May 31, ... ... the ability to attribute calls back to particular advertising campaigns, to monitor the ... teams so that they can maximize conversions and revenue. The software allows customers ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to ... a whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will ... the opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles ...
Breaking Medicine News(10 mins):